cumulative counts across the grant period, negating the need for a separate final report.

Current grant recipients will be able to choose between using the current forms and the revised forms through the completion of their current project. New grant recipients will be required to use the revised forms.

Respondents: There will be three types of respondents to the proposed instruments. First, the direct beneficiaries, the clients receiving supportive services, will participate in the service receipt questionnaire, self-sufficiency matrix, and focus groups, and they will also provide information about their characteristics, needs, and outcomes for the grant recipients' semi-annual reporting. Second, the program directors and social services staff will respond to interview instruments tailored to their roles. Grant recipients will also be asked to complete quarterly PPRs and semi-annual reports to describe their service delivery activities, and outcomes.

Annual Burden Estimates

Burden estimates show the total number of responses per respondent over the next 3 years. The current grant recipients (9 total) will be able to choose between using the current forms and the revised forms through the completion of their current project. New grant recipients (9 new recipients estimated) will be required to use the revised forms.

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Total burden hours	Annual burden hours
Interviews with program directors	18	1	1.5	27	9
Interviews with caseworkers	36	1	1	36	12
Focus groups with residents	50	1	1.5	75	25
Self-sufficiency matrix	1,000	3	1.5	4,500	1,500
Service receipt questionnaire	1,000	3	.25	750	250
Semi-Annual Report Mandatory—original form	9	4	2	72	24
Semi-Annual Report Mandatory—revised form	9	3	3	81	27
Semi-Annual Report Optional—original form	6	4	2	48	16
Semi-Annual Report Optional—revised form	6	3	2	36	12
PPR Narrative Report	18	6	2	216	72

Estimated Total Annual Burden Hours: 1,947.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: Section 1110, Social Security Act, 42 U.S.C. 1310.

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2024–12875 Filed 6–11–24; 8:45 am]

BILLING CODE 4184–24–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Notice of Federal Review of the Alabama Protection and Advocacy System (P&A)

AGENCY: Administration for Community Living, HHS.

ACTION: Notice.

SUMMARY: Representatives of the Administration on Disabilities (AoD), Administration for Community Living (ACL), will be conducting a federal review of the Alabama Protection and Advocacy System (P&A), Alabama Disability Advocacy Program (ADAP) on July 22–26, 2024. AoD is soliciting comments from interested parties on your experiences with the program, and strategies employed by the P&A ADAP in meeting the needs of individuals with developmental disabilities and their families in Alabama.

DATES: Comments from interested parties must be submitted electronically by 11:59 p.m. (ET) by July 31, 2024 in order to be included in the final report.

ADDRESSES: You are encouraged to share your experiences with Selvin Garcia, Administration on Disabilities, Administration for Community Living by email at *Selvin.Garcia@acl.hhs.gov;* by telephone at 202–795–7567; or by mail to Selvin Garcia Administration on Disabilities, Administration for Community Living, 330 C Street SW, 1st Floor, Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Selvin Garcia, Administration on Disabilities, Administration for Community Living, at *Selvin.Garcia@acl.hhs.gov* or 202–795–7567.

Dated: June 6, 2024.

Alison Barkoff,

Principal Deputy Administrator for the Administration for Community Living, performing the delegable duties of the Administrator and the Assistant Secretary for Aging.

[FR Doc. 2024–12824 Filed 6–11–24; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–N–0008]

The Tobacco Products Scientific Advisory Committee; Notice of Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an amendment of the notice of meeting of the Tobacco Products Scientific Advisory Committee (TPSAC). This meeting was announced

in the **Federal Register** of May 6, 2024. The amendment is being made to reflect a change in the **ADDRESSES** portion of the document and to reflect a change in the *Procedure* portion. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Serina Hunter-Thomas, Office of Science, Center for Tobacco Products, Food and Drug Administration, Document Control Center, Bldg. 71, Rm. G335, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 1–877–287–1373, email: *TPSAC@fda.hhs.gov,* or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of May 6, 2024 (89 FR 37231), FDA announced that a meeting of the Tobacco Products Scientific Advisory Committee would be held on June 26, 2024, from 9 a.m. to 4:30 p.m. EST. On page 37232, in the first column, the last paragraph of the **ADDRESSES** portion of the document is changed to read as follows:

For those unable to attend in person, the meeting will also be webcast and will be available at the following link: *https://fda.zoomgov.com/j/1604157441?pwd=YkVzZ28vNHQrVXh3ZlhrTmlHaFVzZz09;* Passcode: H*a5nF.

In addition, on page 37232 in the middle column under *Procedure,* the oral presentations or open public hearing time is now scheduled to start at 11:30 a.m. and end at 12:30 p.m. EST on June 26, 2024.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*) and 21 CFR part 14, relating to the advisory committees.

Dated: June 6, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2024–12784 Filed 6–11–24; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–N–2583]

Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding, Repackaging, and Related Activities Regarding Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with Agency guidance documents pertaining to pharmacies, outsourcing facilities, and other entities with regard to human drug compounding, repackaging, and related activities.

DATES: Either electronic or written comments on the collection of information must be submitted by August 12, 2024.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of August 12, 2024. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2024–N–2583 for ''Human Drug Compounding, Repackaging, and Related Activities Regarding Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit